MedTrace Logo

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2026-03-24

No results posted yet for this study

Summary

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

Conditions

  • Myeloproliferative Neoplasms

Interventions

DRUG

INCA033989

INCA033989 will be administered at protocol defined dose.

DRUG

Ruxolitinib

Rux will be administered according to Prescribing Information/SmPC.

Sponsors & Collaborators

Principal Investigators

  • Incyte Medical Monitor · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-25
Primary Completion
2028-02-29
Completion
2028-02-29
FDA Drug
Yes

Countries

  • Australia
  • Canada
  • Denmark
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05936359 on ClinicalTrials.gov